ConductScience.org, home

Paper6961971

Uptake and metabolism of daunorubicin by human leukemia cells.

DeGregorio MW and 3 others. Cancer Chemother Pharmacol, 1982. Cited by 13 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Uptake and metabolism of daunorubicin by human leukemia cells. Papers, record 6961971. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6961971

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Uptake and metabolism of daunorubicin by human leukemia cells.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1982
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
0.71
iCite
Revised in PubMed
2019-08-29
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1DeGregorio MWM W
2Carrera CJC J
3Klock JCJ C
4Wilbur JRJ R

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DaunorubicinMajor topic
LeukemiaMajor topic
Acute Disease
Animals
Biotransformation
Cell Line
Chromatography, High Pressure Liquid
Humans
Leukemia, Experimental
Leukemia, Myeloid, Acute
Time Factors

Source PubMed

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1276,884Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.Proc Natl Acad Sci U S A1978https://conductscience.org/library/papers/276884PubMed
2535,134Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/535134PubMed
36,104,578Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography.Drug Metab Dispos1980https://conductscience.org/library/papers/6104578PubMed
41,069,608
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.
Cancer Treat Rep1976https://conductscience.org/library/papers/1069608PubMed
54,179,068Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.Scand J Clin Lab Invest Suppl1968https://conductscience.org/library/papers/4179068PubMed
67,428,784Comparative uptake, metabolism and retention of anthracyclines by tumors growing in vitro and in vivo.Eur J Cancer (1965)1980https://conductscience.org/library/papers/7428784PubMed
7498,420Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/498420PubMed
8648,557Uptake and subcellular localization of daunorubicin and adriamycin in cultured fibroblasts.Eur J Cancer (1965)1978https://conductscience.org/library/papers/648557PubMed
9398,688Daunorubicin reductase activity in leukemia leukocyte homogenates.Arch Immunol Ther Exp (Warsz)1979https://conductscience.org/library/papers/398688PubMed
106,945,901An in vitro model for acute myelogenous leukemia chemotherapy.Cancer1981https://conductscience.org/library/papers/6945901PubMed
117,053,847Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin.Cancer Res1982https://conductscience.org/library/papers/7053847PubMed
126,941,824Individual nuclear uptake patterns for adriamycin and daunomycin in human leukemia and lymphoma cells.Blut1981https://conductscience.org/library/papers/6941824PubMed
131,271,407Cellular pharmocodynamics of several anthrocycline antibiotics.J Med Chem1976https://conductscience.org/library/papers/1271407PubMed
147,266,019Differences in uptake of adriamycin and daunomycin by normal BM cells and acute leukemia cell determined by flow cytometry.Leuk Res1981https://conductscience.org/library/papers/7266019PubMed
154,264,560High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.Cancer1972https://conductscience.org/library/papers/4264560PubMed
167,397,945Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/7397945PubMed
176,930,988Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.Cancer Lett1980https://conductscience.org/library/papers/6930988PubMed
18977,683Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography.J Chromatogr1976https://conductscience.org/library/papers/977683PubMed
19271,272Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.Nature1977https://conductscience.org/library/papers/271272PubMed
201,069,571Acute granulocytic leukemia: treatment of the disease.Arch Intern Med1976https://conductscience.org/library/papers/1069571PubMed

See all 22 references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
8,431,976Targeting chemosensitizing doses of toremifene based on protein binding.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8431976PubMed
6,690,077Uptake, metabolism, and cytotoxicity of doxorubicin in human Ewing's sarcoma and rhabdomyosarcoma cells.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6690077PubMed
6,488,444Kinetics and sensitivity of daunorubicin in patients with acute leukemia.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6488444PubMed
3,891,121Uptake and metabolism of daunorubicin by human myelocytic cells.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/3891121PubMed
1,463,871Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells.Breast Cancer Res Treat1992https://conductscience.org/library/papers/1463871PubMed
1,386,843Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells.Invest New Drugs1992https://conductscience.org/library/papers/1386843PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6961971

GET https://conductscience.org/api/papers/v1/6961971/references?page=2